Oncology cartoons by Dr Kanhu Charan Patro

1. DR KANHU CHARAN PATRO
M.D, D.N.B[RT], MBA, FICRO, FAROI, PDCR,
CEPC
www.slideshare.net/search/slideshow?searchfrom=header&q=oncology+cartoons
www.facebook.com/oncologycartoons/photos_albums
96th volume/MARCH 2024
ONCOLOGY CRATOONS EDUCATIVE E-BOOK

5. KRISTIN J/IJROBP/2021 16th FEB 2024/STEREO
ISRS-RECOMMENDATION- BRAIN MET CAVITY SRS

6. STEN MYREHAUG/JNS/2017 17th FEB 2024/STEREO
ISRS-RECOMMENDATION- Reirradiation spine SBRT

8. Clinical Trials the Role of Radiation in the Adjuvant Setting for PDAC
Colin S. Hill/Clinical Colorectal Cancer/2023 19th FEB 2024/ PANCREAS

9. Clinical Trials in the Role of Radiation in the Neoadjuvant or Definitive Therapy for PDAC
Colin S. Hill/Clinical Colorectal Cancer/2023 20th FEB 2024/ PANCREAS

10. Target volume delineation for vulval cancer RCR guidelines
Alexandra J Stewart/The Royal College of Radiologists/2024 21st FEB 2024/ VULVA

11. Target volume delineation for vulval cancer- RCR guidelines
Alexandra J Stewart/The Royal College of Radiologists/2024 22nd FEB 2024/ VULVA

12. GCP parameter for vulval cancer- confined to vulva
Alexandra J Stewart/The Royal College of Radiologists/2024 23rd FEB 2024/ VULVA
1. Labia majora and minora,
clitoris, vestibule, urethral
meatus, introitus, perineum
2. The CTV_Vulva also
includes the GTV_Vulva +10
mm.
3. Consideration can be given
to excluding some areas
from this expansion such as
the legs or outside the
body.
4. 5 mm inside the bone can
be included in this
expansion, to cover
potential periosteal
involvement

13. GCP for vulval cancer- involvement of mons pubis
Alexandra J Stewart/The Royal College of Radiologists/2024 24th FEB 2024/ VULVA
1. Skin bridge between the vulva and inguinal lymph node bilaterally
2. Include whole mons if tumour is involving the mons; also include when treating a primary/postoperative vulval tumour and LN.
3. 5 mm from skin surface if no bolus and to skin surface if bolus
4. It is acceptable not to include the mons in CTV_Vulva if there is a small vulval lesion that lies behind the posterior vaginal wall, even if there are
positive inguinal LN.

14. GCP for vulval cancer- involvement of vagina
Alexandra J Stewart/The Royal College of Radiologists/2024 25th FEB 2024/ VULVA
At least 3 cm of caudal vagina (with consideration of including the entire vaginal length)

15. GCP for vulval cancer- involvement of ANORECTRUM
Alexandra J Stewart/The Royal College of Radiologists/2024 26th FEB 2024/ VULVA

16. GCP for vulval cancer- involvement of URETHRA
Alexandra J Stewart/The Royal College of Radiologists/2024 27thFEB 2024/ VULVA

17. GCP for vulval cancer- Contouring workflow
Alexandra J Stewart/The Royal College of Radiologists/2024 28thFEB 2024/ VULVA

18. NODAL VOLUME IN VULVAL CANCER
Alexandra J Stewart/The Royal College of Radiologists/2024 29th FEB 2024/ VULVA

19. RADIATION DOSE IN VULVAL CANCER
Alexandra J Stewart/The Royal College of Radiologists/2024 1st MARCH 2024/ VULVA

20. OAR CONSTRAINTS IN VULVAL CANCER
Alexandra J Stewart/The Royal College of Radiologists/2024 2nd MARCH 2024/ VULVA

21. Pelvic nodal borders in target delineation
Alexandra J Stewart/The Royal College of Radiologists/2024 3rd MARCH 2024/ VULVA

22. GCP for vulval cancer- involvement of CLITORIS
Alexandra J Stewart/The Royal College of Radiologists/2024 4th MARCH 2024/ VULVA

23. Target delineation workflow in non cranial site
DR KANHU CHARAN PATRO
STEPS GCP EXPLANATION
STEP-1 GTVp Clinicoradiological
STEP-2 CTVp Clinicoradiological + microscopic
STEP-3 GTVn Clinicoradiological
STEP-4 CTVn Clinicoradiological + microscopic
STEP-5 CTVp ELECTIVE Natural pathway of spread
STEP-6 CTVn ELECTIVE Natural pathway of spread
STEP-7 OAR delineation As per need
STEP-8 Special editing Barriers and OAR
STEP-9 PTVLR Institutional and technique based
STEP-10 PTVHR Institutional and technique based
5th MARCH 2024/ TARGET

24. Target delineation workflow in CANCER CERVIX
DR KANHU CHARAN PATRO
STEPS GCP EXPLANATION
STEP-1 GTVp Clinicoradiological
STEP-2 CTVp Cervix
STEP-3 GTVn Clinicoradiological
STEP-4 CTVn Clinicoradiological + 0.5cm
STEP-5 CTVp Elective Uterus + Adnexa + Vagina as per need + Parametrium
STEP-6 CTVn Elective Common iliac+ Internal iliac+ External Iliac + Presacral + Obturator
STEP-7 OAR As per need
STEP-8 Special editing Barriers and OAR [bone + muscle +air]
STEP-9 PTVn Institutional and technique based
STEP-10 PTVp Institutional and technique based
6th MARCH 2024/ TARGET

25. RERT H&N recommendations for resectable disease
Matthew
C./IJROBP/2022
7th MARCH 2024/ RERT

26. RERT H&N recommendations for Unresectable disease and SBRT
8th MARCH 2024/ RERT
Matthew
C./IJROBP/2022

27. REIRRADAIATION IN HEAD & NECK CANCER  WORKFLOW
9th MARCH 2024/ RERT
Matthew
C./IJROBP/2022

28. REIRRADAIATION IN HEAD & NECK CANCER BRAIN STEM DOSE
10th MARCH 2024/ RERT
Matthew
C./IJROBP/2022

29. REIRRADAIATION IN HEAD & NECK CANCER SPINAL CORD DOSE
11th MARCH 2024/ RERT
Matthew
C./IJROBP/2022

30. REIRRADAIATION IN HEAD & NECK CANCER OPTIC CHAISM DOSE
12th MARCH 2024/ RERT
Matthew
C./IJROBP/2022

31. REIRRADAIATION IN HEAD & NECK CANCER OPTIC NERVE DOSE
13th MARCH 2024/ RERT
Matthew
C./IJROBP/2022

32. REIRRADAIATION IN HEAD & NECK CANCER CAROTID ARTERY DOSE
14th MARCH 2024/ RERT
Matthew
C./IJROBP/2022

33. SMOKING INCREASES THE RISK OF KIDNEY CANCER
15th MARCH 2024/ PUBLIC
Smoking tobacco doubles the risk of developing kidney cancer. It is believed to
cause about 30% of kidney cancers in men and about 25% in women.